{"DataElement":{"publicId":"3263643","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinue Clinical Trial Eligibility Criteria Status","preferredDefinition":"a condition or state at a particular time related to the discontinuation of prior administration of platinum-based chemotherapy to treat the primary cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"3192315v1.0:3263638v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3192315","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinue Clinical Trial Eligibility Criteria","preferredDefinition":"information related to the discontinuation of prior administration of platinum-based chemotherapy to treat the primary cancer as an element of a personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3192313v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3192313","version":"1","preferredName":"Prior Platinum Compound Chemotherapy Primary Neoplasm Discontinued Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:Inorganic compounds which contain platinum as the central atom.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04):The original tumor.:Discontinued; stopped permanently or temporarily.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3192313v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Platinum Compound","conceptCode":"C1450","definition":"A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Primary Neoplasm","conceptCode":"C8509","definition":"A tumor at the original site of origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6AC896-D5CE-51E2-E040-BB89AD433F27","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"ONEDATA","dateModified":"2011-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C6AC896-D5DF-51E2-E040-BB89AD433F27","latestVersionIndicator":"Yes","beginDate":"2011-02-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-02-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3263638","version":"1","preferredName":"Prior Platinum Compound Chemotherapy Primary Neoplasm Clinical Trial Eligibility Criteria Status","preferredDefinition":"A condition or state at a particular time for the clinical trial eligibility as it relates to prior platinum compound chemotherapy for primary neoplasm.","longName":"3263638v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable-pt. received more than one cytotoxic regimen","valueDescription":"Not Applicable-pt. received more than one cytotoxic regimen","ValueMeaning":{"publicId":"3263639","version":"1","preferredName":"Not Applicable-pt. received more than one cytotoxic regimen","longName":"3263639","preferredDefinition":"Not Applicable-pt. received more than one cytotoxic regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB33E9FE-6979-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB33E9FE-6992-8F83-E040-BB89AD4323AA","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"ONEDATA","dateModified":"2011-08-23","deletedIndicator":"No"},{"value":"Had persistent disease after platinum therapy","valueDescription":"Had persistent disease after platinum therapy","ValueMeaning":{"publicId":"3263640","version":"1","preferredName":"Had persistent disease after platinum therapy","longName":"3263640","preferredDefinition":"Had persistent disease after platinum therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB33E9FE-699C-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB33E9FE-69B5-8F83-E040-BB89AD4323AA","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"ONEDATA","dateModified":"2011-08-23","deletedIndicator":"No"},{"value":"Progressed during platinum therapy","valueDescription":"Progressed during platinum therapy","ValueMeaning":{"publicId":"3263641","version":"1","preferredName":"Progressed during platinum therapy","longName":"3263641","preferredDefinition":"Progressed during platinum therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB33E9FE-69BF-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB33E9FE-69D8-8F83-E040-BB89AD4323AA","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"ONEDATA","dateModified":"2011-08-23","deletedIndicator":"No"},{"value":"Had a platinum-free interval of less than 12 months","valueDescription":"Had a platinum-free interval of less than 12 months","ValueMeaning":{"publicId":"3263642","version":"1","preferredName":"Had a platinum-free interval of less than 12 months","longName":"3263642","preferredDefinition":"Had a platinum-free interval of less than 12 months","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB33E9FE-69E2-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB33E9FE-69FB-8F83-E040-BB89AD4323AA","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"ONEDATA","dateModified":"2011-08-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB33E9FE-6963-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"ALAIS","dateModified":"2011-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"10000078","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"10000077","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104904","version":"1","longName":"GOG-0186H","context":"NRG"},{"publicId":"4104902","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000502","version":"1","longName":"GOG-0170Q","context":"NRG"},{"publicId":"10000501","version":"1","longName":"GOG-0170Q","context":"NRG"}]}],"AlternateNames":[{"name":"3192315v1.0:3263638v1.0","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"If the patient has received o","type":"Preferred Question Text","description":"If the patient has received only one prior cytotoxic regimen (platinum-based regimen for management of primary disease), has the patient","url":null,"context":"CTEP"}],"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"AB33E9FE-6A05-8F83-E040-BB89AD4323AA","latestVersionIndicator":"Yes","beginDate":"2011-08-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-23","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}